Form Type and Date: 8-K current report filed by Johnson & Johnson on July 15, 2026, reporting events as of the same date Item 8.01 - Results of Operations and Financial Condition: Filing includes disclosure of results of operations and financial condition information Item 9.01 - Financial Statements and Exhibits: Filing includes financial statements and exhibits as supporting documentation…

Our analysis rates this filing BULLISH. This is a standard quarterly earnings announcement filing with no disclosed material risks, legal issues, regulatory actions, or adverse events. The filing structure and content are consistent with normal quarterly reporting practices for a major…

Concern level: MODERATE (2.1/10).

Notable risk changes: 8-K filing contains only Q2 2026 earnings announcement with no material negative events disclosed; Document is a standard quarterly earnings report (Item 2.02) with attached press release and financial statements; No risk factors, litigation, regulatory actions, product recalls, executive changes, or material adverse events mentioned in filing.

The model predicts JNJ will underperform the S&P 500 by about 0.0% over 30 days (model confidence 85%). This is model analysis for research, not investment advice.